A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.

Budde LE, Olszewski AJ, Hu B, Shah NN, Batlevi CL, Yin S, To I, Wei MC, Kallemeijn MJ, Musick L, Lundberg L, Shamas N, Dixon M, Pal N, Shewade A, Westin J.

Open source

DOI: 10.1002/jha2.70351
Published: 2026-08-13
Container: EJHaem
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/jha2.70351,
  title = {A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.},
  author = {Budde LE and  Olszewski AJ and  Hu B and  Shah NN and  Batlevi CL and  Yin S and  To I and  Wei MC and  Kallemeijn MJ and  Musick L and  Lundberg L and  Shamas N and  Dixon M and  Pal N and  Shewade A and  Westin J.},
  year = {2026},
  journal = {EJHaem},
  doi = {10.1002/jha2.70351},
  url = {https://doi.org/10.1002/jha2.70351}
}

RIS

TY  - JOUR
TI  - A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.
AU  - Budde LE
AU  -  Olszewski AJ
AU  -  Hu B
AU  -  Shah NN
AU  -  Batlevi CL
AU  -  Yin S
AU  -  To I
AU  -  Wei MC
AU  -  Kallemeijn MJ
AU  -  Musick L
AU  -  Lundberg L
AU  -  Shamas N
AU  -  Dixon M
AU  -  Pal N
AU  -  Shewade A
AU  -  Westin J.
PY  - 2026
JO  - EJHaem
DO  - 10.1002/jha2.70351
UR  - https://doi.org/10.1002/jha2.70351
ER  -

APA

LE, B., AJ, O., B, H., NN, S., CL, B., S, Y., I, T., MC, W., MJ, K., L, M., L, L., N, S., M, D., N, P., A, S., & J., W. (2026). A Real-World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma.. EJHaem. https://doi.org/10.1002/jha2.70351

Source records

europe-pmc · retrieved 2026-09-25T05:44:04.373Z
doaj · retrieved 2026-09-25T05:44:04.341Z